Dr. Mato Discusses a Phase II Trial of Umbralisib in CLL

Anthony R. Mato, MD
Published: Monday, Jun 25, 2018



Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses a phase II trial of umbralisib in chronic lymphocytic leukemia (CLL).

About one-half of the discontinuations of agents such as ibrutinib (Imbruvica) or idelalisib (Zydelig) have been due to toxicities, says Mato. These side effects tend to be different from agent to agent. This study aims to address this intolerant patient population, which Mato says is a significant unmet need in the CLL landscape. Intolerant on this study was defined as a patient who had 2 or more toxicities that were grade 2 or higher. It must then resolve to grade 1 or less, so that the recurrence of that toxicity while on umbralisib could be tested, Mato explains.

The novel next-generation PI3K inhibitor umbralisib was administered at 800 mg once daily. Relatively few grade 3/4 events have occurred, and the primary endpoint of progression-free survival with a 9.5-month median follow-up has not been reached.


Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses a phase II trial of umbralisib in chronic lymphocytic leukemia (CLL).

About one-half of the discontinuations of agents such as ibrutinib (Imbruvica) or idelalisib (Zydelig) have been due to toxicities, says Mato. These side effects tend to be different from agent to agent. This study aims to address this intolerant patient population, which Mato says is a significant unmet need in the CLL landscape. Intolerant on this study was defined as a patient who had 2 or more toxicities that were grade 2 or higher. It must then resolve to grade 1 or less, so that the recurrence of that toxicity while on umbralisib could be tested, Mato explains.

The novel next-generation PI3K inhibitor umbralisib was administered at 800 mg once daily. Relatively few grade 3/4 events have occurred, and the primary endpoint of progression-free survival with a 9.5-month median follow-up has not been reached.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x